Big Idea Ventures (BIV), through its Generation Food Rural Partners (GFRP) fund, and Mercantile Life Science Ventures IV (MLSV) have made a joint investment in Maia Fertility, an Israel-based biotechnology company developing a sustained-release enzyme platform called Ferizyme™ to improve reproductive outcomes in cattle. The funding amount was not disclosed. The deal marks one of BIV's most direct bets on livestock-input technology, an area drawing increased venture attention as food-system investors look beyond alternative proteins toward upstream agricultural efficiency.
The Technology
Ferizyme™ is a proprietary sustained-release delivery system designed to address reproductive bottlenecks in mammals. In its current commercial focus, the platform targets cattle fertility — a persistent drag on herd productivity and a meaningful cost driver for beef and dairy operators. Maia Fertility says the proceeds will fund efficacy studies on commercial farms in North America and Europe, while also funding refinements to the delivery mechanism to maximize conception rates. The company frames livestock validation as a prerequisite to eventual human reproductive health applications, though no regulatory timeline for the latter was provided.
Why Agri-Food Investors Are Watching
For BIV — a global food, agriculture, and materials investor with more than 100 portfolio companies across 30 countries — the investment fits a familiar pattern of targeting foundational biological challenges in the food supply chain. Tom Mastrobuoni, Chief Investment Officer at Big Idea Ventures, called the cattle market opportunity "immediate" and the pathway into human health "transformative." GFRP, the fund vehicle used in this deal, is an RBIC-licensed vehicle backed by Farm Credit System members including CoBank, Farm Credit Services of America, Compeer Financial, and Mid-America Farm Credit — a capital base oriented toward rural economic development and agricultural commercialization.
Reproductive efficiency has long been a financial lever for livestock operators: lower conception rates translate directly into longer calving intervals, reduced herd turnover, and higher feed costs per unit of output. A technology capable of meaningfully improving first-service conception rates across commercial herds would carry significant value per animal across the beef and dairy sectors. The global cattle artificial insemination and reproductive services market has attracted growing investment as precision livestock management scales, and Ferizyme™ enters a field that includes hormonal synchronization protocols, genetic selection tools, and emerging biologics.
Nir Arbel, Chief Executive Officer of Maia Fertility, said the partnership gives the company the infrastructure "to prove this technology at scale." I. Steven Edelson, CEO of Mercantile Companies Inc., framed reproductive efficiency as central to both healthcare and agriculture, describing the investment as bringing the technology "to the farms and clinics that need it most."
For food and beverage supply-chain observers, the deal is a reminder that protein-supply stability increasingly depends on biological inputs as much as on processing or logistics. Investors tracking alternative-protein and livestock-technology convergence or agri-food venture funding trends will find Maia Fertility's dual-market positioning — cattle now, human health later — a structure common to platform biotechs seeking near-term revenue to subsidize longer regulatory arcs.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
